Biotech has seen a surge in the development of new modalities in recent years. At a16z bio+health, we spend a lot of time thinking about how new modalities fit into increasingly crowded indication landscapes.
Here, @JorgeCondeBio , @adelatomsejova , and I dove into a case study on the ongoing battle for market share in the SMA landscape to ask how patients, clinicians, and the market ultimately determine what counts as "best-in-class".
Take a look and share your thoughts on what other indications we are missing.
a16z.com/outclassed-the-batt…
Welcome, Greg! Thrilled to be working with you!
Join us in welcoming Dr. Greg Verdine as a16z Bio + Health Venture Partner!
With a record of academic leadership, innovative drug discovery & serial entrepreneurial success in biotech, he's a game-changer.
More from @vintweeta + @JorgeCondeBio here: a16z.com/2023/07/20/greg-ver…
Ben Portney retweeted
New @a16zBioHealth Bio Eats World Journal Club episode is out! I had a wonderful time discussing the @Majzner_Lab's new work engineering CAR T cells with true boolean logic gates for improved safety and efficacy. Thanks to Robbie for joining. Listen in! 🎧 bio-eats-world.simplecast.co…
Thrilled to be part of this years team and the opportunity to make an impact on such an important cause! Please consider donating: justgiving.com/fundraising/b…
The #TimmermanTraverse is back! @ldtimmerman is leading 20+ industry leaders up and over 7 mountain peaks to grow support for our programs & partnerships. Learn more: lifesciencecares.org/news/20…
@LS_CaresSD @LS_CaresPhilly
Ben Portney retweeted
In 2020, before she won the @NobelPrize in chemistry, @CarolynBertozzi sat down with Bio Eats World to discuss her work on lysosome-targeting chimeras, which break down proteins gone haywire.
In honor of her win, check out our re-released episode 👇 podcasts.apple.com/us/podcas…
Thrilled to be part of Orbital Tx!! @a16z biohealth
xitter.cf/vintweeta/status/15675…
1/ "In the history of medicine, certain therapeutic classes have revolutionized the treatment of both prevalent and rare diseases, and RNA-based therapeutics is undoubtedly one of them.”
-- @gciaramella1
Excited for the launch of Orbital Tx today! businesswire.com/news/home/2…
Ben Portney retweeted
Cocktail therapies—combos of drugs that attack different parts of a virus—made HIV a manageable condition. Can we use precision cocktails to fight cancer?
IDRx aims to punch back against cancer through intelligently designed combination therapies.
🥊🥊🥊
a16z.com/2022/08/02/investin…
Ben Portney retweeted
Today @FlagshipPioneer announced the close of a $3.4 billion capital pool that will enable us to accelerate the creation and growth of our next-generation bioplatform companies. flagshippioneering.com/press…
Ben Portney retweeted
How can we prepare for the next pandemic? Flagship's Lovisa Afzelius and Alex Goldsmith explain the imperative for a Global Pathogen Shield, focused on discovery, surveillance, and prognostic readiness tools and approaches. @afzelius_lovisa flagshippioneering.com/stori…
Ben Portney retweeted
What makes this the #biotechmoment, and what gives all of us in the field - scientists, entrepreneurs, investors - permission to leap to unexplored places in search of bold new breakthroughs? My thoughts here:
flagshippioneering.com/stori…
Biotech is now hip...hop lnkd.in/eJahTkd
